Previous studies reported positive expression rates of B7-H3 in other human tumor tissues ranging from 37 to 76% due to the use of different scoring systems and antibodies for B7-H3 detection (Sun et al., 2006; Cheng et al., 2018; Inamura et al., 2018; Nehama et al., 2019; Kim et al., 2020). This evidence concerns the gene CD276 and neoplasm.